Bangladesh vs Indonesia: Access to anti-retroviral drugs, female
Bangladesh
33.0%
in 2024
Indonesia
36.0%
in 2024
Bangladesh rank
133rd
Indonesia rank
130th
Access to anti-retroviral drugs, female over time
- Bangladesh
- Indonesia
How they compare
Indonesia currently reports 36.0% against 33.0% in Bangladesh, a difference of 3.0%.
That makes Indonesia's figure about 1.1 times Bangladesh's.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Indonesia ahead.
Bangladesh ranks 133rd and Indonesia ranks 130th of 141 countries.
Bangladesh has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bangladesh | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.7% | 1.3% | 0.4% | Bangladesh |
| 2010s | 16.0% | 12.9% | 3.1% | Bangladesh |
| 2020s | 30.0% | 28.8% | 1.2% | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Bangladesh or Indonesia?
- Indonesia, at 36.0% against 33.0% in Bangladesh as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Bangladesh and Indonesia?
- 3.0%, with Indonesia ahead.
- How many years of comparable data are there for Bangladesh and Indonesia?
- 25 years are reported by both, from 2000 to 2024.
- How do Bangladesh and Indonesia rank globally for access to anti-retroviral drugs, female?
- Bangladesh ranks 133rd and Indonesia ranks 130th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.